Brief: Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv
15/04/2025 12:22
April 15 (Reuters) - Precision BioSciences Inc DTIL.O: PRECISION BIOSCIENCES RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR PBGENE-HBV, A FIRST-IN-CLASS GENE EDITING THERAPY DESIGNED TO ELIMINATE THE ROOT CAUSE OF CHRONIC HEPATITIS B Source text: ID:nBw606zpwa Further company coverage: DTIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision BioSciences
See all newsPrecision Biosciences, Inc reports results for the quarter ended September 30 - Earnings Summary
Precision BioSciences Q3 net loss narrows on non-cash warrant gains
Precision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview